A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Weakness

What recent performance signals about Regeneron Pharmaceuticals (REGN)

With no single headline event driving Regeneron Pharmaceuticals (REGN) today, the stock’s recent performance and current fundamentals offer a useful starting point if you are tracking large cap US biotech names.

Regeneron closed at US$701.42, with shares showing a 0.8% decline over the past day and a 6.7% decline over the past week. The stock is also down about 9.8% over the past month and 5.4% over the past 3 months, while the 1 year total return stands at 16.5%.

Over a longer horizon, Regeneron’s 3 year total return is a 7.3% decline, compared with a 42.2% total return over 5 years. This illustrates how holding period length has influenced outcomes for existing shareholders.

The company reports annual revenue of US$14.9b and net income of US$4.4b, with annual revenue growth of 8.2% and net income growth of 12.1%. Regeneron carries a market cap of about US$71.9b and a value score of 6 on the provided scale.

Regeneron focuses on discovering, developing, manufacturing, and commercializing medicines across several therapeutic areas, including eye diseases, allergic and inflammatory conditions, cardiovascular and metabolic diseases, neurological and infectious diseases, rare diseases, cancer, and hematologic conditions.

Its commercial portfolio includes treatments such as EYLEA for various retinal conditions, Dupixent for atopic dermatitis and asthma, Libtayo for certain skin cancers, Praluent for heterozygous familial hypercholesterolemia, and Kevzara for rheumatoid arthritis. These products help form the revenue base that investors are watching as they assess the stock’s recent pullback.

Regeneron also maintains a series of collaborations that broaden its research and commercial reach. Partners include Bayer on EYLEA and EYLEA 8 mg, Alnylam Pharmaceuticals on RNAi therapeutics for eye and central nervous system diseases, Intellia Therapeutics on CRISPR/Cas9 based therapies, Hansoh Pharmaceuticals on a dual GLP 1/GIP receptor program, Tessera Therapeutics on a gene editing therapy for Alpha 1 antitrypsin deficiency, and Telix Pharmaceuticals on radiopharmaceutical therapies.

Given this mix of established products, active partnerships, and a value score of 6, the current share price and recent return profile may prompt investors to reassess how Regeneron fits within a broader healthcare allocation.

See our latest analysis for Regeneron Pharmaceuticals.

Regeneron’s recent pullback, including a 6.7% 7 day share price return decline and a 9.8% 30 day share price return decline from US$701.42, contrasts with its 16.5% 1 year total shareholder return. This suggests shorter term momentum is fading after a stronger longer term outcome.

If you are weighing Regeneron against other healthcare names, it can help to see how the market is pricing AI focused drug developers and platforms, starting with 33 healthcare AI stocks

With REGN trading at US$701.42 and indications of a discount to some valuation estimates, the question for you is simple: is this recent weakness a genuine entry point, or is the market already factoring in future growth?

Most Popular Narrative: 19.7% Undervalued

Regeneron’s most followed narrative puts fair value at $873.78 per share, well above the last close of $701.42, which frames a clear valuation gap for you to assess.

Regeneron’s broad and advancing pipeline, including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity, positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.

Read the complete narrative.

Curious what sits behind that projected earnings climb and premium future P/E multiple assumptions? The narrative leans on specific growth, margins, and buyback forecasts that could surprise you.

Result: Fair Value of $873.78 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on EYLEA avoiding sharper competitive and pricing pressure, and on heavy R&D and manufacturing spend translating into commercially meaningful new drugs.

Find out about the key risks to this Regeneron Pharmaceuticals narrative.

Next Steps

With sentiment split between recent share price weakness and a popular undervaluation view, it helps to move quickly and test the numbers yourself. To see what investors are optimistic about, start by reviewing the company’s 4 key rewards

Looking for more investment ideas?

If you are serious about sharpening your watchlist, do not stop at a single biotech name. Use the Simply Wall Street Screener to compare opportunities side by side and keep fresh ideas coming.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com